Ovoca Bio is a clinical-stage biopharmaceutical company with a focus on women's health. They acquired IVIX in 2018, a biotechnology company that develops Orenetide, a groundbreaking treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Ovoca Bio has been dedicated to furthering the clinical development and commercial planning of Orenetide since the acquisition.

They have submitted the treatment for marketing authorization in Russia and have initiated a Phase II study in a western population with HSDD. Ovoca Bio's vision is to become a leader in the research and development of novel medicines that address significant unmet needs for women. They have filed for approval to market Orenetide in Russia and are actively developing this drug for major global markets, particularly focusing on the US and Europe.

The company is open to licensing commercialization rights and collaborating with pharmaceutical companies to expedite the availability of their product candidates to patients in need. With a strong patent portfolio, experienced team, and top advisors, Ovoca Bio is well-positioned to achieve its corporate goals in women's health